EHA 2017 | T-Cell engaging treatment in AML
Marion Subklewe
• 22 Jun 2017
Marion Subklewe, MD, from the LMU-University Hospital, Munich, Germany, expresses how allogeneic stem cell transplantation is the mother of immunotherapy, which has proven the power of T-Cells. She summarises the topics in her talk, which focused on exploring alternative tools which are now evolving to recruit T-Cells for therapeutic strategies in acute myeloid leukemia (AML). Recently, a human, phase I multi-centre trial (NCT02520427) has been initiated which will administer AMG-330 for relapse-refractory AML, and a classical 3+3 design over the next 36 months to gather further data. Recorded at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.
